Related Experiment Video
Updated: Aug 6, 2026
11:04
Preparation of Enantiopure Non-Activated Aziridines and Synthesis of Biemamide B, D, and epiallo-Isomuscarine
Published on: June 13, 2022
Novel benzimidazole-based MCH R1 antagonists
Andrew J Carpenter1, Kamal A Al-Barazanji, Kevin K Barvian
1Metabolic and Viral Diseases Centre of Excellence for Drug Discovery, GlaxoSmithKline, Five Moore Drive, Research Triangle Park, NC 27709, USA. andrew.j.carpenter@gsk.com
Bioorganic & Medicinal Chemistry Letters
|August 15, 2006
Summary
Researchers optimized benzimidazole compounds as melanin-concentrating hormone receptor 1 (MCH R1) antagonists. These novel MCH R1 antagonists demonstrated effectiveness in an animal model of obesity, offering potential therapeutic strategies.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Neuroscience
Background:
- Melanin-concentrating hormone receptor 1 (MCH R1) plays a role in regulating energy balance.
- Dysregulation of MCH R1 signaling is implicated in metabolic disorders like obesity.
Purpose of the Study:
- To identify and optimize novel benzimidazole-based antagonists targeting MCH R1.
- To evaluate the pharmacokinetic properties and in vivo efficacy of these MCH R1 antagonists.
Main Methods:
- High-throughput screening to identify initial MCH R1 antagonist hits.
- Structure-activity relationship (SAR) studies for lead optimization.
- Pharmacokinetic profiling and in vivo efficacy testing in an animal model of obesity.
Main Results:
- Identification of a screening hit that led to the development of a benzimidazole-based MCH R1 antagonist series.
- Optimization of compounds to achieve favorable structure-activity relationships and pharmacokinetic profiles.
- Demonstration of significant efficacy of a lead MCH R1 antagonist in reducing body weight in an animal model of obesity.
Conclusions:
- Benzimidazole derivatives represent a promising class of MCH R1 antagonists.
- Optimized MCH R1 antagonists hold potential for the treatment of obesity.
Related Concept Videos
01:15Anthelminthic Agents
Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
01:24Cholinergic Antagonists: Pharmacokinetics
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and the conjunctiva.
01:29Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic antagonists are called...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...